Personalized medicine by the use of mathematical models for angiogenesis: validation in a Mesenchymal Chondrosarcoma patient
|
|
- Colleen Chase
- 5 years ago
- Views:
Transcription
1 Personalized medicine by the use of mathematical models for angiogenesis: validation in a Mesenchymal Chondrosarcoma patient Agur Zvia Institute for Medical BioMathematics, IMBM
2 Agenda Medical problem: No scientific methods for forecasting patient s response to drug > Trial-and-Error Solution: BioMathematics can relate molecular changes to their effects on the patient The rationale of our angiogenesis modeling: search the dominant dynamics in Xenograft experiments construct simple (qualitative) mathematical model that describe the dynamics how simple? to learn what the minimal model structure that yields the dynamics is Modeling aim: model should enable predicting treatment efficacy vascular tumor growth model Validation in Pre/Clinical trials Use: treatment personalization The patient Model personalization Prospective preclinical model validation Predictions for the patient Prospective clinical validation Summary and open questions
3 Problem: Intracellular Interactions do not Suffice for Forecasting Patient Response March 22, 2004
4 cf cn Out (1 mm) Tumor (in) Xenograft experiments in ovary carcinoma
5 M I/f M o/f I/f M o/f I/o F I/f F o/f F I/o Mouse P -- f-3 f Analysis of xenograft experiments in ovary carcinoma Vessels volume 5 0 V tum tumor size Vessels volume M mature vessels F total vessels I inside tumor O-O outside tumor n,f reference sites For example: M o/f relates to the volume of mature vessels outside the tumor in relation to the reading in reference site f M I/n I/n M o/n M I/o I/o F F I/n I/n F F o/n F F I/o I/o Mouse GA - - n- n3 V tum Arakelyan et al., in: "Cancer Modelling and Simulation", Luigi Preziosi ed., CRC Press, LLC, (UK), tumor size
6 simplifyed model and its analysis Effective vessel density Time delay effect on tumor proliferation Tumor size - rate of change Protein1 - secretion rate (VEGF) Protein2 - secretion rate (Ang1) Immature vessel volume - rate of change Mature vessel volume - rate of change Agur et al, DCDS, 2004 N& = f1( E 1 τ ) N P & 1= f2( E) N δ 1P1 P & 2 = αn δ 2P2 V & 1= f3( P1 τ2) V1 f4( P2 ) V1 + f5( P V & 2 = f4( P2 ) V1 f5( P2 τ ) V 3 2 2τ 3 ) V 2 produced by the tumor at a rate which is a decreasing function, f2, of the effective vessel density produced by the tumor and decays at constant rates produced as a function f3 of VEGF; matures as an increasing function, f4, of ang1/ang2 For rationalizing the observed oscillation pattern it was necessary to introduce a significant time-delay between the tumor and vessels processes. This might underline the significance of time-delays in tumor growth dynamics.
7 Model response to antiangiogenic drugs Model has to Yield oscillation Take account of tumor growth Take account of new vessel formation and regression Consider different time scales of vasculature and tumor processes (to represent time delays) Enable modelling of drugs with different drug action mechanisms Rationalize and organize current angiogenesis information We organized the information scattered in experimental articles into one vascular tumor growth algorithm
8 Multiscale mechanistic model of vascular tumor progression Multi-scale mathematical model of vascular tumor growth. Tissues (light orange), cells (pink) and molecules (lavender); Vascular Endothelial Growth Factor (VEGF) and Platelet- Derived Growth Factor (PDGF) are secreted by the tumor cells. VEGF binds to endothelial cells and PDGF to pericytes, to generate new and mature blood vessels, respectively, and the ratio of Angiopoietin1 (Ang1) and Angiopoietin2 (Ang2), secreted both by the tumor and by endothelial cells, affects the stability of the mature vessels. Arakelyan et al., ASCO, 02; Angiogenesis, 02; Agur, Future Oncology, 10
9 Model simulations of mouse GA: Tumor volume/time cf cn Out (1 mm Medium increase 15 volume units in 1 month Tumor (in)
10 Validation of the Vascular Tumor Model: Demonstrating Prediction Accuracy The vascularization profile of tumor GA was predicted and compared with the actual MVD, experimentally measured by MRI. Model Predictions MRI readings SI Arakelyan et al., EJC, 2004 time Total vasculature Mature vessels Immature vessels
11 Clinical validation in metastatic breast cancer (MBC) patients treated by Docetaxel Model accurately predicted objective tumor response (RECIST) and tumor sizes/entire treatment period Predicted vs. measured tumor diameter. Model prediction accuracy of tumor size: R 2 =0.7 (p<0.001); objective tumor response assessed according to RECIST; 85.7% (Kappa=0.72, p<0.05). Regression model line (solid line); 95% confidence interval (dashed line).
12 Main processes in the solid tumor model - partial scheme of Vascular Tumor Model Tumor growth and angiogenesis are regulated by Effective Vessel Density (EVD). EVD represents the level of perfusion in the system which affect: Living Cells EVD Apoptotic /Necrotic Cells Proliferation rate Cell Death: Apoptosis and necrosis Growth factor generation Creation/maturation of vessels VEGF Immature Vessels Vessels Cells Ang2 Ang1 Mature Vessels PDGF
13 Mathematical Formulation: System of Ordinary Differential Equations (Example) λ M Living Cells µ A Apoptotic /Necrotic Cells dl dt L() t µ f L() t ( EVD) ( EVD) = up f up (EVD) λ Proliferation Rate M f EVD EVD Vessels Cells f down (EVD) down A Death Rate EVD
14 Mathematical Formulation Integration of PD into Mechanistic Model Possible Drug Effects Reduce proliferation rate Increase rate of cell death Angiogenic processes λ M Living Cells µ A Apoptotic /Necrotic Cells dl dt PD down (C) 0.5 PD Effect on Proliferation Conc f EVD PD Effect on Death Conc Vessels Cells down up PD ( C()) t λ ( EVD) L() t PD ( C()) t µ ( EVD) L() t = M M up A A down PD up (C) 4 2 f
15 Treatment Personalization A new treatment personalization method, combining tumor xenografts and the vascular tumor growth model was put forward, validated and used to suggest an improved treatment schedule for a particular Mesenchyma ChondroSarcoma (MCS) patient Gorelik et al., Cancer Research, 68: (21) 2008, PP
16 Mesenchymal Chondrosarcoma (MCS) MCS accounts for about 1% of all chondrosarcomas Overall, 5-year survival is 55% This disease usually follows an aggressive course, with a high rate of distant metastases Rare condition = deficiency in experience
17 The patient VN a 45-year old white male in excellent health Growing mediastinal mass was found in 2004 Primary tumor was resected Multiple new bilateral pulmonary nodules thirty days after the operation. Aggressive chemotherapy with Ifosphamide, cisplatin and etoposide for 6 cycles, VACA (vincristine, doxorubicin, cyclophosphamide, and dactinomycin) for 2 cycles, and sunitinib orally for 8 weeks Additional liver and bone metastases Severe myelosuppression with pancytopenia
18 Methodology
19 Model predictions of treatment efficacy and prospective validation in xenograft experiments Gorelik et al, 2008 Regimen Drug Dose (mg/kg) Route Schedule Predicted Results (TGI 1 ) Observed Results (TGI 1 ) Accuracy 1 Control % 2 CPT-11 Bevacizumab IP IP Q7Dx3 Q3Dx % 59.4 % 96.2 % Gemcitabine 40 IP Q3Dx4 3 Docetaxel 6.3 IV Q2Dx % % 70.1 % Bevacizumab 10 IP Q3Dx10 4 Doxorubicin Bevacizumab 2 10 IV IP QDx5 Q3Dx % 56.4% 84.2 % 5 Sorafenib 60 PO QDx % 38.9% 96.1 % 6 Sorafenib Bevacizumab PO IP QDx10 Q3Dx % 87.2 % 81.4 % 1 Tumor Growth Inhibition Average prediction accuracy: 87.2 %
20 Scaling to human The scaling was done using expression analysis of several key proteins Ang1, Ang2, VEGF, etc
21 Treatment Personalization Predictions of improved schedule in the MCS patient Gorelik et al, 2008 Regimens containing Bevacizumab applied intravenously in combination with onceweekly Docetaxel are predicted more efficacious in the MCS patient than all other simulated Docetaxel schedules.
22 Treatment Personalization Predictions Weekly Docetaxel in the patient resulted in stable metastatic disease and relief of pancytopenia Gorelik et al, 2008
23 Summary Mathematical models can formalize complex drug-patient interactions The minimal model describing the observed oscillatory pattern of angiogenesis was designed.. showing that a time-delay between the tumor and vessels processes drives the oscillations On this basis a detailed multiscale angiogenesis model was constructed yielding precise predictions of drug efficacy Successful validation enables models to be employed for identifying improved regimens & personalize treatment A successful treatment personalization endeavor improves patient s survival and quality of life Once weekly Docetaxel is advantageous for patients with intense angiogenesis
24 Selected publications 1. Arakelyan L, Vainstain V., Agur Z. A computer algorithm describing angiogenesis and vessel maturation and its use for studying the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth, Angiogenesis, 5 (3), 2002 (pp ). First comprehensive model for cancer angiogenesis. 2. Agur Z., Arakelyan L., Daugulis P., Ginosar Y. Hopf point analysis for angiogenesis models. Discrete and Continuous Dynamical Systems Series B, 4 (1), 2004 (pp ). Mathematical analysis determining the driving forces in angiogenesis. 3. Arakelyan L, Merbl Y., Agur Z. Vessel maturation effects on tumour growth: validation of a computer model in implanted human ovarian carcinoma spheroids Eur. Jour. Cancer, 41, 2005 (pp ). Experimental validation of the comprehensive model. 4. Gorelik B., Ziv I., Shohat R., Wick M., Webb C., Hankins D., Sidransky D., Agur Z. Efficacy of once weekly docetaxel combined with bevacizumab for patients with intense angiogenesis: validation of a new theranostic method in mesenchymal chondrosarcoma xenografs. Cancer Research, 68: (21) November, , PP Use of angiogenesis model for treatment personalization prospective validation in man. 5. Arakelyan L., Merbl Y., Daugulis P., Ginosar Y., Vainstein V., Selister V., Kogan Y., Harpak H., Agur Z. Multi-scale analysis of angiogenic dynamics and therapy, Ch. 7, in: "Cancer Modelling and Simulation", Luigi Preziosi ed., CRC Press, LLC, (UK), Book chapter on rationale of angiogenesis modelling. 6. Z Agur, N Bloch, B Gorelik, M Kleiman, Y Kogan, Y Sagi, D Sidransky, Y Ronen. Developing oncology drugs using virtual patients of vascular tumor diseases. In "Systems biology in Drug Discovery and Development"; Ed. Daniel L. Young and Seth Michelson; Series: Technologies for the Pharmaceutical Industry; Series Editor: Dr. Sean Ekins; John Wiley & Sons, Book chapter on use of angiogenesis modelling in the clinic and Pharma industry.
25 Thank You
26 Paolo Magni Is the model unique (best) for retrieving the system at hand? How can you validate the precision of the PK/PD model? Time scale of accuracy?
27 Discussion modelling angiogenesis What type of models should we use to describe angiogenesis? Stochastic models vs. deterministic models Discrete vs. continuous ODE vs. PDE Simple vs. complex Analytical vs. simulations Statistical vs. mathematical Top-down vs. bottom-up Biochemistry-driven vs. physics-driven Data-driven vs. mechanism-driven Spatial vs. mass action. An ill-defined question
28 Model Evaluation 1. Does the model add insight to the problem at hand? 2. Are the model assumptions about the driving forces in the biological system sufficiently justified? If the problem at hand is qualitative, then satisfying 1 and 2 may suffice If the model is expected to yield quantitative predictions 3. How robust are the model s predictions? 4. What are the data to be used for model validation? 5. What is the time scale over which prediction is to be made? 6. Over how long it yields consistent and precise predictions? 7. What are the limitations of the model?
29 Do mathematical models of angio. add insight? They can underline the critical parameters (bistability) They can predict comprehensive behaviour in response to small changes upstream They can predict population response to a drug Due to variations in disease parameters Due to varaition in PK Etc. They can be used to personalize medicine (theranostics)
30 Collaboration Collaboration bet experimentalists and theorists is mutually important: The experimentalist direct and help refining the theory and, reciprocally, aided by it to refine their view of the important (vs secondary or even negligible) forces in the system. How can we join forces? How can we collaborate to improve the angio. modelling? Of different solid cancer indication? Get good human disease model (data on untreated?)?.
BMBF Forsys Partner Project: A Systems Biology Approach towards Predictive Cancer Therapy
ling and ling and BMBF Forsys Partner Project: A Systems Biology Approach towards Predictive Cancer Therapy H. Perfahl, A. Lapin, M. Reuss Germany holger.perfahl@ibvt.uni-stuttgart.de 1 ling and Cooperation
More informationCancer Metronomic Therapy Milan, February 26, 2016
Cancer Metronomic Therapy Milan, February 26, 2016 Metronomic Chemotherapy: Evolution and Development of the Concept Robert S. Kerbel, PhD Senior Scientist Sunnybrook Research Institute Professor, Dept.
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More information1.The metastatic cascade. 2.Pathologic features of metastasis. 3.Therapeutic ramifications
Metastasis 1.The metastatic cascade 2.Pathologic features of metastasis 3.Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of bone Paget s disease of the
More informationNexavar in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase II Study in Advanced Breast Cancer: Nexavar in Combination with Chemotherapy Demonstrates 74 Percent Improvement
More informationRationale for VEGFR-targeted Therapy in RCC
Rationale for VEGFR-targeted Therapy in RCC EIKCS, Budapest, May 2013 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial Management Group Honoraria Astra Zeneca + + + Astellas
More information1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize?
1. The metastatic cascade 3. Pathologic features of metastasis 4. Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of Paget s disease of the nipple (intraductal
More informationThe Angiopoietin Axis in Cancer
Ang2 Ang1 The Angiopoietin Axis in Cancer Tie2 An Overview: The Angiopoietin Axis Plays an Essential Role in the Regulation of Tumor Angiogenesis Growth of a tumor beyond a limiting size is dependent upon
More informationPKPD models to describe the growth and inhibition of xenograft tumors by
Applying mechanistic c PKPD models to describe the growth and inhibition of xenograft tumors by targeted anti-cancer agents. James WT Yates, Neil Evans, RD Owen Jones, Mike Walker, Patricia Schroeder,
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationNGR-TNF selectively binds to tumor blood vessels via CD13, inducing the activation of caspases and promoting apoptotic endothelial cell death in vivo
AACR 100 th Annual Meeting 2009 Denver NGR-TNF selectively binds to tumor blood vessels via CD13, inducing the activation of caspases and promoting apoptotic endothelial cell death in vivo The NGR-hTNF
More informationStructured models for dengue epidemiology
Structured models for dengue epidemiology submitted by Hannah Woodall for the degree of Doctor of Philosophy of the University of Bath Department of Mathematical Sciences September 24 COPYRIGHT Attention
More informationOMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University
More informationDeveloping Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic. Kevin G. McLure, PhD EpiCongress July 2014
Developing Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic Kevin G. McLure, PhD EpiCongress July 2014 Zenith Epigenetics Overview Formed from Resverlogix as an independent
More informationMechanisms of Resistance to Antiangiogenic. Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012
Mechanisms of Resistance to Antiangiogenic Agents Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012 Angiogenesis: A fundamental attribute of cancer Premise of Anti-angiogenic
More informationFor personal use only
ASX and Media release 6 April 211 Circadian s Inhibits Tumour Growth in Models of Lung, Ovarian and Prostate Cancer Data demonstrates efficacy of with other therapeutic agents in mouse models of lung,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationSignaling Vascular Morphogenesis and Maintenance
Signaling Vascular Morphogenesis and Maintenance Douglas Hanahan Science 277: 48-50, in Perspectives (1997) Blood vessels are constructed by two processes: vasculogenesis, whereby a primitive vascular
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationRIP-Tag2 mouse model as a Paradigm for Target. Search in NETs
RIP-Tag2 mouse model as a Paradigm for Target Search in NETs Oriol Casanovas, Ph.D. Tumor Angiogenesis Group INSTITUT CATALÀ d ONCOLOGIA IDIBELL Barcelona (SPAIN) Therapeutic Targeting of the Tumor Stroma
More informationMedia Release. Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer. Basel, 08 February 2011
Media Release Basel, 08 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Avastin study in recurrent, platinum-sensitive ovarian cancer showed women lived
More informationMathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials
Mathematical-Statistical Modeling to Inform the Design of HIV Treatment Strategies and Clinical Trials 2007 FDA/Industry Statistics Workshop Marie Davidian Department of Statistics North Carolina State
More informationMathematics Meets Oncology
.. Mathematics Meets Oncology Mathematical Oncology Philippe B. Laval Kennesaw State University November 12, 2011 Philippe B. Laval (Kennesaw State University)Mathematics Meets Oncology November 12, 2011
More informationUNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL PhD THESIS THE IMPORTANCE OF TUMOR ANGIOGENESIS IN CEREBRAL TUMOR DIAGNOSIS AND THERAPY ABSTRACT PhD COORDINATOR: Prof. univ. dr. DRICU Anica PhD
More informationForm 2023 R2.0: Ovarian Cancer Pre-HSCT Data
Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More informationThe Process of Angiogenesis & Inhibition of Angiogenesis and/or Lymphangiogenesis
The Process of Angiogenesis & Inhibition of Angiogenesis and/or Lymphangiogenesis Nam Deuk Kim, Ph.D. Pusan National University Contents Part 1. The process of angiogenesis Part 2. The role of angiopoietins
More informationVision of the Future: Capecitabine
Vision of the Future: Capecitabine CHRIS TWELVES Cancer Research Campaign Department of Medical Oncology, University of Glasgow, and Beatson Oncology Centre, Glasgow, United Kingdom Key Words. Capecitabine
More informationA PHASE 1 STUDY OF TRC105 (ANTI- ADVANCED SOLID TUMORS
ASCO 2011 Abstract Number: 3073 A PHASE 1 STUDY OF TRC105 (ANTI- CD105 ANTIBODY) IN PATIENTS WITH ADVANCED SOLID TUMORS J. W. Goldman, M. S. Gordon, H. Hurwitz, R. Pili, D. S. Mendelson, B. J. Adams, D.
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationAdvances in Chemotherapy for Non-Small Cell Lung Cancer
Advances in Chemotherapy for Non-Small Cell Lung Cancer Evan W. Alley, MD, PhD Clinical Associate Professor Abramson Cancer Center at Penn Presbyterian Lung Cancer: Overview Second most common cancer in
More informationSTUDY OF TRC093 (HUMANIZED ANTI- CLEAVED COLLAGEN ANTIBODY) IN PATIENTS WITH SOLID CANCER
FINAL RESULTS FROM A PHASE 1 STUDY OF TRC093 (HUMANIZED ANTI- CLEAVED COLLAGEN ANTIBODY) IN PATIENTS WITH SOLID CANCER F Robert, MS Gordon, LS Rosen, DS Mendelson, M Mulay, BJ Adams, D Alvarez, CP Theuer,
More informationNovel Molecular Molecular Therapies In Hepatocarcinoma Prof Eric
Novel Molecular Therapies In Hepatocarcinoma Prof. Eric Raymond Department of Médical Oncology Hôpital Beaujon, Clichy Université Paris 7 Denis Diderot INSERM-U728 eric.raymond@bjn.aphp.fr HCC is a highly
More informationPROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC
PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC Giorgia Mangili RUF ginecologia oncologica medica IRCCS San Raffaele Milano mangili.giorgia@hsr.it STANDARD CHEMOTHERAPY The standard chemotherapy
More informationCancer Treatment Using Multiple Chemotheraputic Agents Subject to Drug Resistance
Cancer Treatment Using Multiple Chemotheraputic Agents Subject to Drug Resistance J. J. Westman Department of Mathematics University of California Box 951555 Los Angeles, CA 90095-1555 B. R. Fabijonas
More informationDevelopment of Rational Drug Combinations for Oncology Indications - An Industry Perspective
Development of Rational Drug Combinations for Oncology Indications An Industry Perspective Stuart Lutzker, MDPhD Vice President Oncology Early Development Genentech Inc 1 Conventional Oncology Drug Development
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationList of Publications
List of Publications Zvia Agur Summer, 2016 A. PEER-REVIEWED ARTICLES: 1. Agur Z, Halevi-Tobias K, Kogan Y & Shlagman O. 2016. Employing dynamical computational models for personalizing cancer immunotherapy.
More informationBayer to Present New Data on Advancing Oncology Portfolio. New Preclinical and Early Clinical Data Evaluating Innovative Compounds in Drug Development
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com 105 th Annual Meeting American Association for Cancer Research Bayer to Present
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationNintedanib in Oncology Backgrounder
For media outside the US, UK and Canada only Nintedanib in Oncology Backgrounder 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. Additional clinical data 5. Nintedanib approval
More informationAdverse side effects associated to metronomic chemotherapy
Adverse side effects associated to metronomic chemotherapy Elisabetta Munzone, MD Division of Medical Senology Istituto Europeo di Oncologia Milano, Italy LDM: the optimal biological dose Although there
More informationPharmaceuticals and mathematics input in the era of precision medicine. Dr. Joseph Ciccolini SMARTc - Pharmacokinetics Unit CRCM Inserm U1068 & APHM
Pharmaceuticals and mathematics input in the era of precision medicine Dr. Joseph Ciccolini SMARTc - Pharmacokinetics Unit CRCM Inserm U1068 & APHM ANTICANCER DRUGS 2.0. Goals: To ensure optimal use of
More informationClinical Management Guideline for Small Cell Lung Cancer
Diagnosis and Staging: Key Points 1. Ensure a CT scan that is
More informationStergios Moschos, MD
Stergios Moschos, MD Clinical Associate Professor of Medicine Department of Medicine Division of Hematology/Oncology University of North Carolina at Chapel Hill Solid Tumor with one of the Highest Mutation
More informationPKPD modelling to optimize dose-escalation trials in Oncology
PKPD modelling to optimize dose-escalation trials in Oncology Marina Savelieva Design of Experiments in Healthcare, Issac Newton Institute for Mathematical Sciences Aug 19th, 2011 Outline Motivation Phase
More informationMeasures with Ultrasound Contrast Agents. Contrast-Enhanced Ultrasound Monitoring Tumor Response to Therapy
4/1/2 Measures with Ultrasound Contrast Agents Kenneth Hoyt, PhD, MBA Departments of Radiology and Biomedical Engineering Comprehensive Cancer Center University of Alabama at Birmingham Contrast-Enhanced
More informationInvestor Update. Basel, 21 October 2018
Investor Update Basel, 21 October 2018 Updated data showed that Roche's Tecentriq in combination with Avastin shrank tumours in people with unresectable or advanced hepatocellular carcinoma (HCC) Data
More informationSTATE OF THE ART 4: Combination Immune Therapy-Chemotherapy. Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI)
STATE OF THE ART 4: Combination Immune Therapy-Chemotherapy Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI) Topics for Consideration What are the rules for integrating
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationAngiogenesis Targeted Therapies in Renal Cell Carcinoma
Angiogenesis Targeted Therapies in Renal Cell Carcinoma John S. Lam, MD Department of Urology David Geffen School of Medicine University of California-Los Angeles Patient Case CC: Abdominal pain VS: T
More informationPractice of Medicine-1 Ovarian Cancer Clinical Correlation
Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by
More informationAnti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
DOI 10.1007/s10456-014-9420-y REVIEW PAPER Anti-angiogenic for cancer: current progress, unresolved questions and future directions Naveen S. Vasudev Andrew R. Reynolds Received: 15 July 2013 / Accepted:
More informationDAWNING OF THE AGE OF ANGIOGENESIS
DAWNING OF THE AGE OF ANGIOGENESIS Bob Leibowitz, M.D. DIPLOMATE AMERICAN BOARDS OF INTERNAL MEDICINE AND SUBSPECIALTIES OF MEDICAL ONCOLOGY AND HEMATOLOGY December 1997 April 2004 (Revised) Angiogenesis
More informationGap identification as a critical step to enable integrated clinical trial simulation platforms
Gap identification as a critical step to enable integrated clinical trial simulation platforms Application to TB Eline van Maanen Joost de Jongh Peter Vis September 26, 2013 LEIDEN EXPERTS ON ADVANCED
More informationPATHOBIOLOGY OF NEOPLASIA
PATHOBIOLOGY OF NEOPLASIA Department of Pathology Gadjah Mada University School of Medicine dr. Harijadi Blok Biomedis, 6 Maret 2009 [12] 3/17/2009 1 The pathobiology of neoplasia Normal cells Malignant
More informationCancer: recent advances and implications for underwriting
Cancer: recent advances and implications for underwriting Robert Rubens Select 74 Bristol 25 February 2010 Agenda Epidemiology - changing mortality Evidence-base for underwriting breast cancer ovarian
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationEDUCATIONAL SEMINAR. Humanized Mouse Models in Pre- Clinical Efficacy Studies in Oncology. BIOCOM CRO Event January 23, 2018
EDUCATIONAL SEMINAR Humanized Mouse Models in Pre- Clinical Efficacy Studies in Oncology BIOCOM CRO Event January 23, 2018 Agenda 8.00 8.30 Registration and networking 8.30 8.45 Introduction, by Jussi
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationPhase 1 Trial of ALN-VSP in Cancers Involving the Liver. Annual Meeting of the Controlled Release Society August 2, 2011
Phase 1 Trial of ALN-VSP in Cancers Involving the Liver Annual Meeting of the Controlled Release Society August 2, 2011 Agenda ALN-VSP: Background Phase 1 Trial Study Design Safety Data Tumor Response
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationModeling of cancer virotherapy with recombinant measles viruses
Modeling of cancer virotherapy with recombinant measles viruses Thomas W. Carr Department of Mathematics Southern Methodist University Dallas, TX Collaborators: Krešimir Josić Dept. of Mathematics, University
More informationOptimizing Drug Regimens in Cancer Chemotherapy
Optimizing Drug Regimens in Cancer Chemotherapy A. ILIADIS, D. BARBOLOSI Department of Pharmacokinetics, Faculty of Pharmacy University of Méditerranée 27, bld. Jean Moulin, 13385 Marseilles Cedex 5 FRANCE
More informationBreast cancer. Prof Arlene Chan Medical Oncologist Director Breast Clinical Trials Unit, Mount Hospital Vice-Chair Breast Cancer Research Centre - WA
Breast cancer rof Arlene Chan Medical Oncologist Director Breast Clinical Trials Unit, Mount Hospital Vice-Chair Breast Cancer Research Centre - WA Breast cancer Incidence of Breast Cancer by Stage at
More informationStatistical modelling of primary Ewing tumours of the bone
Statistical modelling of primary Ewing tumours of the bone Sreepurna Malakar Department of Chemistry and Biochemistry University of Alaska, U.S.A. Florentin Smarandache Department of Mathematics and Statistics
More informationInhibitors of Methionine Aminopeptidase-2 2 in the Treatment of Non-Hodgkin
Inhibitors of Methionine Aminopeptidase-2 2 in the Treatment of Non-Hodgkin Hodgkin s s Lymphoma Targeted Cancer Therapies William Westlin, Ph.D. Vice President, Preclinical Research Discovery of Fumagillin
More informationTumor Growth rates to better capture therapeutic activity in cancer patients
Tumor Growth rates to better capture therapeutic activity in cancer patients Charles Ferté MD PhD Statistical and biomedical models for imaging in cancer Apr 2016, 8th - ISPED Serge Koscielny 2 Background
More informationPre-clinical PK/PD modelling of combination therapies in oncology: abemaciclib and vemurafenib
Pre-clinical PK/PD modelling of combination therapies in oncology: abemaciclib and vemurafenib Combination Therapies in Oncology Combination therapies in oncology have been explored and used for many decades
More informationAngiogenesis in Ovarian Cancer
Angiogenesis in Ovarian Cancer Dr Shibani Nicum Consultant Medical Oncologist and Lead for Gynae- Oncology Oxford University Hospitals Content 1. Epithelial Ovarian Cancer : epidemiology 2. Angiogenesis-normal
More informationMedia Release. Basel, 17 May 2018
Media Release Basel, 17 May 2018 Phase III IMpower150 study showed Roche s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly
More informationMedia Release. Basel, 6 th February 2018
Media Release Basel, 6 th February 2018 Phase III IMmotion151 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain
More informationInnovazioni Terapeutiche In Oncologia Dott. Massimo Ghiani A USL N 8 Ospedale A. Businco Oncologia Medica III. Tarceva TM
Innovazioni Terapeutiche In Oncologia Dott. Massimo Ghiani A USL N 8 Ospedale A. Businco Oncologia Medica III Tarceva TM Tarceva TM (erlotinib HCl) High-affinity, reversible inhibitor of HER1/EGFR Tyrosine
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationRoche announces final phase III study results of Avastin plus radiotherapy and chemotherapy in people with an aggressive form of brain cancer
Media Release Basel, 1 June 2013 Roche announces final phase III study results of Avastin plus radiotherapy and chemotherapy in people with an aggressive form of brain cancer Roche (SIX: RO, ROG; OTCQX:
More informationClinical Pipeline Highlights
Clinical Pipeline Highlights Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 25 MDX-7: Anti-PSMA HuMAb for Prostate Cancer Biology PSMA expressed
More informationIt s s Always Something!
It s s Always Something! New Approaches in Brain Tumor Treatment Virginia Stark-Vance, M.D. When Something Is a Brain Tumor Brain tumors aren t rare: there are over 100,000/yr Most originate as other cancers
More information2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized
More informationMedia Release. Basel, 26 March 2018
Media Release Basel, 26 March 2018 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live
More informationMedia Release. Basel, 7 May 2018
Media Release Basel, 7 May 2018 FDA grants priority review to Roche s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer Roche
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationBevacizumab for the treatment of recurrent advanced ovarian cancer
Bevacizumab for the treatment of recurrent advanced ovarian cancer ERRATUM This report was commissioned by the NIHR HTA Programme as project number 11/40 Page 2 This document contains errata in respect
More informationMedical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia
Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)
More informationA mathematical model for the primary tumor of mcrc
A mathematical model for the primary tumor of mcrc Marta Leocata Joint work with F.Flandoli, C. Ricci, M.C. Polito, V. De Mattei December 2, 2016 University of Pisa Plan of the talk General Project; A
More informationNew Biological and Immunological Therapies for Cancer
New Biological and Immunological Therapies for Cancer Sant P. Chawla, M.D., FRACP The Sarcoma Oncology Center, Santa Monica CA 90403 7 th International Conference on Drug Discovery &Therapy 1 Promising
More informationBevacizumab 10mg/kg 14 days
INDICATIONS FOR USE: Bevacizumab 10mg/kg 14 days Regimen Code 00212a *Reimbursement status Hospital INDICATION ICD10 In combination with fluoropyrimidine-based chemotherapy C18 for treatment of adult patients
More informationciap using fragment based drug discovery
Discovery of a potent dual antagonist of both XIAP and ciap using fragment based drug discovery Gianni Chessari, PhD TAT Congress 2012 Disclosures I am an employee of Astex Pharmaceuticals I will present
More informationMulti-Mechanism Drugs for Oncology and Inflammation. September 2007
Multi-Mechanism Drugs for Oncology and Inflammation September 2007 1 Forward-Looking Statements Statements that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties.
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Avastin (bevacizumab) Policy Number: MP-030-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationRole of DE-CT in Oncology
Role of DE-CT in Oncology Dushyant Sahani, M.D Director of CT Associate Professor of Radiology Massachusetts General Hospital Harvard Medical School Email-dsahani@partners.org Disclosure Research Grant
More informationBNC105 Results Presentation
Creating and developing innovative therapies BNC105 Results Presentation Dr Deborah Rathjen CEO & Managing Director, Bionomics Limited Dr José Iglesias Chief Medical Officer, Bionomics Limited Dr Tom Hutson
More informationNEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)
NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Kristin Reed (650) 467-9831 FDA APPROVES AVASTIN IN COMBINATION WITH CHEMOTHERAPY
More information[ NASDAQ: MSHL ] Southern California Investor Conference August 29, 2011
[ NASDAQ: MSHL ] Southern California Investor Conference August 29, 2011 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events
More informationStivarga. Stivarga (regorafenib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.26 Subject: Stivarga Page: 1 of 5 Last Review Date: September 15, 2017 Stivarga Description Stivarga
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More information